• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

化脓性汗腺炎的转录组分析:具有广泛免疫激活的独特分子特征。

Transcriptomic Analysis of Hidradenitis Suppurativa: A Unique Molecular Signature with Broad Immune Activation.

机构信息

Department of Dermatology and Venereology, Aarhus University Hospital, 8200 Aarhus, Denmark.

出版信息

Int J Mol Sci. 2023 Nov 30;24(23):17014. doi: 10.3390/ijms242317014.

DOI:10.3390/ijms242317014
PMID:38069342
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10707244/
Abstract

Hidradenitis suppurativa is a chronic inflammatory skin disease with limited treatment options. The poorly understood pathogenesis hinders the development of effective treatments; therefore, a pressing need exists to further elucidate the molecular mechanisms in hidradenitis suppurativa. This study investigated the underlying inflammatory pathways and cell types in hidradenitis suppurativa using transcriptomic approaches with RNA sequencing of lesional and non-lesional skin biopsies from hidradenitis suppurativa, which was jointly analyzed with previously published transcriptomic data from atopic dermatitis and psoriasis patients. The differential expression and pathway enrichment analyses demonstrated the activation of multiple inflammatory processes, including the innate and adaptive immune systems, implicated in the hidradenitis suppurativa pathogenesis. In agreement, hidradenitis suppurativa exhibited a unique and heterogeneous cell type signature involving lymphoid and myeloid cells such as B cells and macrophages. Furthermore, hidradenitis suppurativa displayed increased expression of T1/2/17 signatures with no predominant T signatures unlike psoriasis (T1/17) and atopic dermatitis (T2). In summary, our study provides molecular insights into the pathomechanisms in hidradenitis suppurativa, revealing a strong and widespread immune activation, which may benefit from treatment strategies offering a broad immunomodulation of various key inflammatory pathways. Our data not only corroborate previously reported findings but also enhance our understanding of the immune dysregulation in hidradenitis suppurativa, uncovering novel and potential therapeutic targets.

摘要

化脓性汗腺炎是一种慢性炎症性皮肤病,治疗选择有限。发病机制理解不足阻碍了有效治疗方法的发展;因此,迫切需要进一步阐明化脓性汗腺炎的分子机制。本研究采用 RNA 测序技术,对化脓性汗腺炎患者皮损和非皮损皮肤活检组织进行转录组分析,联合分析了特应性皮炎和银屑病患者的先前发表的转录组数据,以此研究化脓性汗腺炎的潜在炎症途径和细胞类型。差异表达和通路富集分析表明,多种炎症过程被激活,包括先天和适应性免疫系统,这与化脓性汗腺炎的发病机制有关。一致的是,化脓性汗腺炎表现出独特且异质的细胞类型特征,涉及淋巴细胞和髓样细胞,如 B 细胞和巨噬细胞。此外,与银屑病(T1/17)和特应性皮炎(T2)不同,化脓性汗腺炎显示出 T1/2/17 特征的表达增加,而没有占主导地位的 T 特征。总之,我们的研究为化脓性汗腺炎的发病机制提供了分子见解,揭示了强烈而广泛的免疫激活,这可能受益于提供各种关键炎症途径广泛免疫调节的治疗策略。我们的数据不仅证实了先前报道的发现,而且还增强了我们对化脓性汗腺炎免疫失调的理解,揭示了新的潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/fdb5294f692d/ijms-24-17014-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/a91fba88acef/ijms-24-17014-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/a918961ce0ad/ijms-24-17014-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/a682dc80b82a/ijms-24-17014-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/b76e1ed329d0/ijms-24-17014-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/8d208800e8d4/ijms-24-17014-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/fdb5294f692d/ijms-24-17014-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/a91fba88acef/ijms-24-17014-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/a918961ce0ad/ijms-24-17014-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/a682dc80b82a/ijms-24-17014-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/b76e1ed329d0/ijms-24-17014-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/8d208800e8d4/ijms-24-17014-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620b/10707244/fdb5294f692d/ijms-24-17014-g006.jpg

相似文献

1
Transcriptomic Analysis of Hidradenitis Suppurativa: A Unique Molecular Signature with Broad Immune Activation.化脓性汗腺炎的转录组分析:具有广泛免疫激活的独特分子特征。
Int J Mol Sci. 2023 Nov 30;24(23):17014. doi: 10.3390/ijms242317014.
2
Targeting dysbiosis in psoriasis, atopic dermatitis, and hidradenitis suppurativa: the gut-skin axis and microbiome-directed therapy.靶向银屑病、特应性皮炎和化脓性汗腺炎中的菌群失调:肠-皮肤轴和微生物组导向治疗。
Clin Dermatol. 2023 Sep-Oct;41(5):640-649. doi: 10.1016/j.clindermatol.2023.09.019. Epub 2023 Oct 9.
3
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo.特应性皮炎、化脓性汗腺炎和白癜风的皮肤免疫及其失调。
Cell Cycle. 2020 Feb;19(3):257-267. doi: 10.1080/15384101.2019.1707455. Epub 2020 Jan 5.
4
A review of IL-36: an emerging therapeutic target for inflammatory dermatoses.白细胞介素-36综述:炎症性皮肤病的新兴治疗靶点
J Dermatolog Treat. 2022 Sep;33(6):2711-2722. doi: 10.1080/09546634.2022.2067819. Epub 2022 Apr 26.
5
A Hidradenitis Suppurativa molecular disease signature derived from patient samples by high-throughput RNA sequencing and re-analysis of previously reported transcriptomic data sets.基于高通量 RNA 测序和对先前报道的转录组数据集的重新分析,从患者样本中提取的化脓性汗腺炎分子疾病特征。
PLoS One. 2023 Apr 6;18(4):e0284047. doi: 10.1371/journal.pone.0284047. eCollection 2023.
6
Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study: Classification: Epidemiology.慢性炎症性皮肤病患者中炎症性肠病的发生:一项队列研究:分类:流行病学。
Br J Dermatol. 2022 Nov;187(5):692-703. doi: 10.1111/bjd.21704. Epub 2022 Aug 3.
7
B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab.对阿达木单抗治疗无应答的重度化脓性汗腺炎的 B 细胞和补体特征。
Br J Dermatol. 2023 Jan 23;188(1):52-63. doi: 10.1093/bjd/ljac007.
8
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎:可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
9
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.皮肤科和性病科在莫斯塔尔临床医院用阿达木单抗治疗两例化脓性汗腺炎。
Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110.
10
Secukinumab in the treatment of hidradenitis suppurativa.司库奇尤单抗治疗化脓性汗腺炎。
Immunotherapy. 2023 Dec;15(17):1449-1457. doi: 10.2217/imt-2023-0103. Epub 2023 Oct 16.

引用本文的文献

1
Transcriptomic Signatures and Molecular Pathways in Hidradenitis Suppurativa-A Narrative Review.化脓性汗腺炎的转录组特征和分子途径——一篇叙述性综述
Int J Mol Sci. 2025 Aug 9;26(16):7704. doi: 10.3390/ijms26167704.
2
IRAK4 Targeting: A Breakthrough Approach to Combat Hidradenitis Suppurativa.靶向IRAK4:治疗化脓性汗腺炎的突破性方法。
Biologics. 2025 Jun 30;19:387-397. doi: 10.2147/BTT.S525106. eCollection 2025.
3
Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa.联合靶向肿瘤坏死因子-α和OX40L作为化脓性汗腺炎的一种新治疗选择。

本文引用的文献

1
Systemic Antibiotic Therapy in Hidradenitis Suppurativa: A Review on Treatment Landscape and Current Issues.化脓性汗腺炎的全身抗生素治疗:治疗现状与当前问题综述
Antibiotics (Basel). 2023 May 29;12(6):978. doi: 10.3390/antibiotics12060978.
2
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
3
A Hidradenitis Suppurativa molecular disease signature derived from patient samples by high-throughput RNA sequencing and re-analysis of previously reported transcriptomic data sets.
J Allergy Clin Immunol Glob. 2025 Apr 23;4(3):100483. doi: 10.1016/j.jacig.2025.100483. eCollection 2025 Aug.
4
Unlocking the Mechanisms of Hidradenitis Suppurativa: Inflammation and miRNA Insights.揭开化脓性汗腺炎的发病机制:炎症与微小RNA的见解
Clin Cosmet Investig Dermatol. 2024 Dec 11;17:2829-2846. doi: 10.2147/CCID.S483871. eCollection 2024.
基于高通量 RNA 测序和对先前报道的转录组数据集的重新分析,从患者样本中提取的化脓性汗腺炎分子疾病特征。
PLoS One. 2023 Apr 6;18(4):e0284047. doi: 10.1371/journal.pone.0284047. eCollection 2023.
4
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial.司库奇尤单抗治疗化脓性汗腺炎的疗效和安全性:一项2期随机安慰剂对照试验
Dermatol Ther (Heidelb). 2023 May;13(5):1099-1111. doi: 10.1007/s13555-023-00913-3. Epub 2023 Mar 9.
5
Heat shock protein 90 inhibitor RGRN-305 potently attenuates skin inflammation.热休克蛋白 90 抑制剂 RGRN-305 可有效抑制皮肤炎症。
Front Immunol. 2023 Feb 7;14:1128897. doi: 10.3389/fimmu.2023.1128897. eCollection 2023.
6
Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.古塞单抗治疗化脓性汗腺炎的 II 期、开放标签、作用机制研究。
Br J Dermatol. 2023 Apr 20;188(5):601-609. doi: 10.1093/bjd/ljad010.
7
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.司库奇尤单抗治疗中重度化脓性汗腺炎(SUNSHINE和SUNRISE研究):两项相同的多中心、随机、安慰剂对照、双盲3期试验的第16周和第52周结果
Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3.
8
CSL324, a granulocyte colony-stimulating factor receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa.CSL324,一种粒细胞集落刺激因子受体拮抗剂,可阻断在化脓性汗腺炎中上调的中性粒细胞迁移标志物。
Br J Dermatol. 2023 Apr 20;188(5):636-648. doi: 10.1093/bjd/ljad013.
9
Hidradenitis suppurativa: bacteriological study in surgical treatment.化脓性汗腺炎:外科治疗中的细菌学研究
Postepy Dermatol Alergol. 2022 Dec;39(6):1101-1105. doi: 10.5114/ada.2022.119008. Epub 2022 Sep 9.
10
Transcriptome Meta-Analysis Confirms the Hidradenitis Suppurativa Pathogenic Triad: Upregulated Inflammation, Altered Epithelial Organization, and Dysregulated Metabolic Signaling.转录组元分析证实了化脓性汗腺炎的发病三联征:炎症上调、上皮组织改变和代谢信号失调。
Biomolecules. 2022 Sep 25;12(10):1371. doi: 10.3390/biom12101371.